| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pamela U Fred. Somatostatin analogs in acromegaly. The Journal of clinical endocrinology and metabolism. vol 87. issue 7. 2002-08-02. PMID:12107192. |
somatostatin analogs in acromegaly. |
2002-08-02 |
2023-08-12 |
Not clear |
| Ferenc Laczi, Sándor Magony, János Jules. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide]. Orvosi hetilap. vol 143. issue 19 Suppl. 2002-07-02. PMID:12063861. |
[current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide]. |
2002-07-02 |
2023-08-12 |
Not clear |
| V Esposito, D Esposito, G Lo Iudic. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR]. Minerva endocrinologica. vol 26. issue 4. 2002-05-09. PMID:11782718. |
recently, octreotide (oc) and, more recently, octreotide lar (oc-lar), a new slow-release formulation of the long-acting somatostatin analog, have been regarded as the primary treatment for acromegaly. |
2002-05-09 |
2023-08-12 |
Not clear |
| C Parkinson, W M Drake, M E Roberts, K Meeran, G M Besser, P J Traine. A comparison of the effects of pegvisomant and octreotide on glucose, insulin, gastrin, cholecystokinin, and pancreatic polypeptide responses to oral glucose and a standard mixed meal. The Journal of clinical endocrinology and metabolism. vol 87. issue 4. 2002-04-25. PMID:11932320. |
standard medical therapy for patients with acromegaly includes somatostatin analogs. |
2002-04-25 |
2023-08-12 |
human |
| b' E Comets, F Mentr\\xc3\\xa. Evaluation of tests based on individual versus population modeling to compare dissolution curves. Journal of biopharmaceutical statistics. vol 11. issue 3. 2002-04-08. PMID:11725926.' |
this study is aimed at comparing dissolution curves obtained for several batches of sustained release formulations of octreotide, a somatostatin analog used in acromegaly. |
2002-04-08 |
2023-08-12 |
Not clear |
| Maria Rosaria Ambrosio, Paola Franceschetti, Marta Bondanelli, Mauro Doga, Pietro Maffei, Roberto Baldelli, Guido Tamburrano, Nicola Sicolo, Andrea Giustina, Ettore C degli Ubert. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism: clinical and experimental. vol 51. issue 3. 2002-03-26. PMID:11887179. |
efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. |
2002-03-26 |
2023-08-12 |
Not clear |
| G Zieliński, J K Podgórski, A Koziarski, J Siwik, W Zgliczyński, W Wieliczk. [Preoperative administration of a slow releasing somatostatin analog (SR-lanreotide, BIM 23014) in patients with acromegaly in the course of GH-releasing adenoma]. Neurologia i neurochirurgia polska. vol 35. issue 3. 2002-01-30. PMID:11732266. |
[preoperative administration of a slow releasing somatostatin analog (sr-lanreotide, bim 23014) in patients with acromegaly in the course of gh-releasing adenoma]. |
2002-01-30 |
2023-08-12 |
Not clear |
| W M Drak. Experience with pegvisomant in the treatment of acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 11 Suppl A. 2002-01-28. PMID:11527081. |
established modalities of therapy for acromegaly (surgical adenomectomy, external beam pituitary irradiation, oral dopamine agonists, and injectable somatostatin analogues) have as their common goal the lowering of circulating growth hormone (gh) levels, with a consequent reduction in serum insulin-like growth factor i (igf-i). |
2002-01-28 |
2023-08-12 |
Not clear |
| R Cozzi, M Barausse, M Sberna, A Lodrini, A Franzini, G Lasio, R Attanasi. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary. vol 3. issue 4. 2002-01-24. PMID:11788011. |
lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. |
2002-01-24 |
2023-08-12 |
Not clear |
| R Cozzi, M Barausse, M Sberna, A Lodrini, A Franzini, G Lasio, R Attanasi. Lanreotide 60 mg, a longer-acting somatostatin analog: tumor shrinkage and hormonal normalization in acromegaly. Pituitary. vol 3. issue 4. 2002-01-24. PMID:11788011. |
somatostatin analogues are nowadays the milestone in the medical treatment of acromegaly. |
2002-01-24 |
2023-08-12 |
Not clear |
| J Schopohl, B Gut. [Therapy of pituitary diseases. What can be achieved with medication and hormones?]. MMW Fortschritte der Medizin. vol 143. issue 44. 2002-01-16. PMID:11732393. |
while dopamine agonists and somatostatin analogues are usually administered to acromegaly patients only after unsuccessful surgery, dopamine agonists are the treatment of choice in patients with prolactinomas. |
2002-01-16 |
2023-08-12 |
Not clear |
| D Ferone, R Pivonello, S Lastoria, A Faggiano, M L Del Basso de Caro, P Cappabianca, G Lombardi, A Cola. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clinical endocrinology. vol 54. issue 4. 2002-01-03. PMID:11318782. |
gh and prl cosecretion frequently occurs in acromegaly and the sensitivity of both hormones to somatostatin analogs (sa) and dopamine agonists (da) alone or in combination, is still debated. |
2002-01-03 |
2023-08-12 |
Not clear |
| M S Ip, K C Tan, W C Peh, K S La. Effect of Sandostatin LAR on sleep apnoea in acromegaly: correlation with computerized tomographic cephalometry and hormonal activity. Clinical endocrinology. vol 55. issue 4. 2001-11-01. PMID:11678830. |
this study evaluates the relationship among biochemical activity, sleep apnoeic activity and upper airway anatomic profile in acromegaly, and the effect of sandostatin lar, a long-acting somatostatin analogue, on these parameters. |
2001-11-01 |
2023-08-12 |
human |
| R Attanasio, M Barausse, R Cozz. GH/IGF-I normalization and tumor shrinkage during long-term treatment of acromegaly by lanreotide. Journal of endocrinological investigation. vol 24. issue 4. 2001-10-18. PMID:11383906. |
new depot somatostatin analogs such as lanreotide-slow release (lan) represent a significant improvement in the medical treatment of acromegaly. |
2001-10-18 |
2023-08-12 |
Not clear |
| N M Boulis, A J Noordmans, A Barkan, J Hassing, W F Chandle. Somatotropinoma infarction during octreotide therapy leading to bilateral cavernous sinus syndrome. Pituitary. vol 3. issue 3. 2001-10-11. PMID:11383484. |
the cyclic somatostatin analog, octreotide, forms the mainstay of medical treatment for acromegaly. |
2001-10-11 |
2023-08-12 |
Not clear |
| E Ballarè, L Persani, A G Lania, M Filopanti, E Giammona, S Corbetta, S Mantovani, M Arosio, P Beck-Peccoz, G Faglia, A Spad. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. The Journal of clinical endocrinology and metabolism. vol 86. issue 8. 2001-09-06. PMID:11502816. |
introduction of somatostatin analogs has greatly contributed to improving the prognosis of acromegaly. |
2001-09-06 |
2023-08-12 |
Not clear |
| G Tulipano, C Bonfanti, G Milani, B Billeci, A Bollati, R Cozzi, G Maira, W A Murphy, C Poiesi, S Turazzi, A Giustin. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology. vol 73. issue 5. 2001-08-02. PMID:11399907. |
we conclude that the availability of somatostatin analogs selective for sstr5 will enhance the treatment potency and spectrum in acromegaly. |
2001-08-02 |
2023-08-12 |
human |
| J M Nea. Successful pregnancy in a woman with acromegaly treated with octreotide. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 6. issue 2. 2001-07-12. PMID:11421531. |
to report a successful pregnancy in a 43-year-old woman with acromegaly and treatment during pregnancy with the somatostatin analogue octreotide, to review the physiologic aspects of acromegaly during pregnancy, and to discuss treatment options. |
2001-07-12 |
2023-08-12 |
Not clear |
| A Colao, D Ferone, P Marzullo, P Cappabianca, S Cirillo, V Boerlin, I Lancranjan, G Lombard. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. The Journal of clinical endocrinology and metabolism. vol 86. issue 6. 2001-07-05. PMID:11397887. |
long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. |
2001-07-05 |
2023-08-12 |
Not clear |
| C Scarpignato, I Pelosin. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy. vol 47 Suppl 2. 2001-05-17. PMID:11275699. |
on the other hand, clinical experience with somatostatin analogs in the treatment of conditions like acromegaly and gep tumors has shown that they are well tolerated compared to other antineoplastic therapies currently in use. |
2001-05-17 |
2023-08-12 |
human |